Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry
Revista Española de Cardiología (English Edition) · 2025
DOI: 10.1016/j.rec.2024.07.003 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Española de Cardiología (English Edition), 2025. Verfasst von David García-Vega und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain; Departamento de Cardiología, Hospital Clíni…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) reduce cardiovascular events through different mechanisms, but their association with cancer remains unclear. The aim of this study was to compare the effect of combined treatment (SGLT2i and GLP1ra) and monotherapy (SGLT2i or GLP1ra) on hospitalization and/or death from cancer in a general population and a subgroup of patients with cardiovascular disease (CVD). METHODS: We conducted a nonconcurrent observational prospective study of patients prescribed SGLT2i, GLP1ra, or both. Multinomial propensity scores were performed in the entire population and in a subgroup of patients with CVD. A multivariate Cox regression analysis was used to determine the hazard ratio (HR) for age, sex, risk factors, and treatment for each outcome. RESULTS: We included 14 709 patients (11366 with SGLT2i, 1016 with GLP1ra, and 2327 with both treatments) from treatment initiation. Diabetes was present in 97% of the patients. The subgroup with CVD included 4957 (33.7%) patients. After a median of 33 months of follow-up, the risk of adverse cancer events was similar between patients with and without CVD (3.4% or 3.7%, respectively). The main risk factors for cancer mortality were male sex and age. Combined treatment and its duration reduced the risk of cancer mortality compared with monotherapy with SGLT2i or GLP1ra in the overall population (HR, 0.2216; 95%CI, 0.1106-0.4659; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Medicina, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain; Departamento de Cardiología, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain;…
- Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Spain; Centro de Salud de Milladoiro-Ames, Área Sanitaria de Santiago de Compostela, A Coruña, Spain.
- Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, A Coruña, Spain.
- Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, A Coruña, Spain.
Zitieren
APA
García-Vega, D., Cinza-Sanjurjo, S., Tilves-Bellas, C., Eiras, S., & González-Juanatey, J. R. (2025). Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2024.07.003
Vancouver
García-Vega D, Cinza-Sanjurjo S, Tilves-Bellas C, Eiras S, González-Juanatey JR. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry. Revista Española de Cardiología (English Edition). 2025. doi:10.1016/j.rec.2024.07.003
BibTeX
@article{GarcaVega2025,
author = {García-Vega, David and Cinza-Sanjurjo, Sergio and Tilves-Bellas, Carlos and Eiras, Sonia and González-Juanatey, José R},
title = {Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry},
journal = {Revista Española de Cardiología (English Edition)},
year = {2025},
doi = {10.1016/j.rec.2024.07.003}
}
EUVIMED